MCL1 and lung cancer: In both non–small cell lung cancer (NSCLC) and CRC, Mcl1 accumulation—frequently ascribable to FBXW7-inactivating mutations—leads to intrinsic and acquired resistance to oxaliplatin, 5-FU and several TKIs [16,21,27,46].